New report published by Global Info Research which offers insights on the global Drugs for Vulvovaginal Candidiasis market.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Click to view the full report TOC, figure and tables:
Global Drugs for Vulvovaginal Candidiasis Market: Forecast by Type / Application / Region
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The major players in global Drugs for Vulvovaginal Candidiasis market include: Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical and Kingyork Group.
On the basis of Formulation Types split into: Cream, Pessary and Other.
On the basis on the end applications covers: Hospital & Clinic and Pharmacy.
In the last several years, global market of Drugs for Vulvovaginal Candidiasis developed steadily, with an average growth rate of 5.5%. In 2017, global sales revenue of Drugs for Vulvovaginal Candidiasis is nearly 770 M USD; the actual sale is about 175 million units.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
Ask for Discount on Research Report and Request Sample Copy of Report@
GlobalInfoResearch is a report publisher, a customer, interest-based suppliers. Is in the best interests of our clients, they determine our every move. At the same time, we have great respect for the views of customers. With the improvement of the quality of our research, we develop custom interdisciplinary and comprehensive solution. For further development, we will do better and better. GlobalInfoResearch will with excellent professional knowledge and experience to carry out all aspects of our business. At the same time, we will thoroughly look for information, to give a more comprehensive development.
United States Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
Europe Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
North America Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
Asia-Pacific Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
China Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
EMEA Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
Global Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
Contact US :
Sales Director (Global Info Research)
Tel: +86-13660489451 00852-58197708(HK)
Add: RM 1605C HO KING COMM CTR 2-16 FA YUEN ST MONGKOK KL Hong Kong